Get the Stockscreener App
2.845
1.06%
-0.025
Tempest Therapeutics Inc stock is traded at $2.845, with a volume of 25,525.
It is down -1.06% in the last 24 hours and down -10.58% over the past month.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
See More
Previous Close:
$2.82
Open:
$2.82
24h Volume:
25,525
Relative Volume:
0.23
Market Cap:
$14.02M
Revenue:
-
Net Income/Loss:
$-43.10M
P/E Ratio:
-0.2927
EPS:
-9.7212
Net Cash Flow:
$-36.82M
1W Performance:
-1.76%
1M Performance:
-10.58%
6M Performance:
-60.87%
1Y Performance:
-77.39%
1-Day Range:
$2.75
$2.91
1-Week Range:
$2.75
$3.04
52-Week Range:
$2.75
$13.26
Tempest Therapeutics Inc Stock (TPST) Company Profile
Name
Tempest Therapeutics Inc
Sector
Industry
Phone
415-798-8589
Address
2000 SIERRA POINT PARKWAY, BRISBANE
Compare TPST with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TPST
Tempest Therapeutics Inc
|
2.845 | 13.89M | 0 | -43.10M | -36.82M | -9.7212 |
|
VRTX
Vertex Pharmaceuticals Inc
|
466.70 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.49 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
393.09 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.04 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.03 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Tempest Therapeutics Inc Stock (TPST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-10-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-14-24 | Initiated | Scotiabank | Sector Outperform |
| Feb-08-24 | Initiated | Jefferies | Buy |
Tempest Therapeutics Inc Stock (TPST) Latest News
Tempest Therapeutics, Inc.Common Stock (NQ: TPST - FinancialContent
Market Outlook: Will Tempest Therapeutics Inc stock pay special dividendsJuly 2025 Drop Watch & Real-Time Buy Signal Alerts - moha.gov.vn
Tempest Therapeutics (TPST) Stock Price, Quote, News & History - Benzinga
Will Tempest Therapeutics Inc. stock beat EPS estimatesJuly 2025 Weekly Recap & Weekly High Potential Stock Alerts - bolumsonucanavari.com
How sustainable is Tempest Therapeutics Inc. stock dividend payout2025 Winners & Losers & Verified Momentum Stock Alerts - Улправда
Will Tempest Therapeutics Inc. stock split again soonJuly 2025 Earnings & Accurate Intraday Trading Signals - Улправда
Tempest Therapeutics closes $4.25 million registered direct offering By Investing.com - Investing.com India
Tempest Therapeutics Closes $4.3 Million Direct Offering - MarketScreener
Tempest Therapeutics closes $4.25 million registered direct offering - Investing.com
Tempest Therapeutics : Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules - MarketScreener
Tempest Therapeutics, Inc. Completes Registered Direct Offering and Private Placement, Raising Approximately $4.25 Million - Quiver Quantitative
Tempest Announces Closing of Up To $8.35 Million Registered - GlobeNewswire
[8-K] Tempest Therapeutics, Inc. Reports Material Event | TPST SEC FilingForm 8-K - Stock Titan
Form 8-KCurrent report - ADVFN
Tempest Therapeutics stock falls after $4.25 million direct offering - MSN
[424B5] Tempest Therapeutics, Inc. Prospectus Supplement (Debt Securities) - Stock Titan
Form 424B5 Tempest Therapeutics, - StreetInsider
Tempest Therapeutics stock falls after $4.25 million direct offering By Investing.com - Investing.com UK
Tempest Therapeutics raises $4.25 million in registered direct offering - Investing.com
Tempest Therapeutics Inc (TPST) Performance and Fundamentals Dashboard tells a completely different story - setenews.com
Tempest Therapeutics raises $4.25 million in registered direct offering By Investing.com - Investing.com India
Tempest Therapeutics (Nasdaq: TPST) prices $4.25M offering with $4.1M warrant upside - Stock Titan
Butterfly Network, Citius Pharma Drive Biotech Momentum In After-Hours Trading - Nasdaq
Is Tempest Therapeutics Inc. stock ready for breakoutMarket Growth Report & Growth Oriented Trade Recommendations - newser.com
Will Tempest Therapeutics Inc. stock outperform growth indexesTrend Reversal & Fast Exit/Entry Strategy Plans - newser.com
Tempest Therapeutics Announces New Leadership and Acquisition - MSN
Tempest Therapeutics to acquire Factor Bioscience’s CAR-T programs By Investing.com - Investing.com Australia
Check Out Tempest Therapeutics Inc (TPST)’s Trade Data Rather Than the Analysts’ Views - Setenews
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
What technical signals suggest for Tempest Therapeutics Inc. stockJuly 2025 Sentiment & Expert Curated Trade Ideas - newser.com
Will Tempest Therapeutics Inc. stock go up soonProduct Launch & Safe Entry Trade Signal Reports - newser.com
Tempest Therapeutics Stock Plummets Nearly 50% Amid Shareholder Dilution Fears Following CAR-T Acquisition - Markets Financial Content
Tempest gains CAR Ts for 65% of the company; stock drops - BioWorld MedTech
Why Tempest Therapeutics Inc. stock appeals to dividend seekersQuarterly Portfolio Report & Verified Momentum Watchlists - newser.com
Tempest Therapeutics to acquire Factor Bioscience's CAR-T programs By Investing.com - Investing.com Nigeria
Is Tempest Therapeutics Inc. stock poised for growthWeekly Trade Analysis & Scalable Portfolio Growth Ideas - newser.com
TPST Stock Plummets After Inking Deal To Acquire CAR-T Programs From Privately-Held Firm In All-Stock Transaction - MSN
Tempest Therapeutics to acquire Factor Bioscience’s CAR-T programs - Investing.com India
Tempest Therapeutics stock plunges after all-stock acquisition By Investing.com - Investing.com South Africa
Why Tempest Therapeutics (TPST) Stock Is Down 45% Today - Benzinga
Tempest Therapeutics stock plunges after all-stock acquisition - Investing.com India
Is Tempest Therapeutics Inc. stock undervalued vs historical averages2025 Top Decliners & Expert Approved Trade Ideas - newser.com
Tempest Therapeutics Inc Stock (TPST) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.60%
0.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):